Hims & Hers Health (HIMS) Stock Overview
Operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
HIMS Community Fair Values
Create NarrativeSee what 901 others think this stock is worth. Follow their fair value or set your own to get alerts.
Hims: The Platform Powering Personalised Healthcare
Hims & Hers Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.84 |
| 52 Week High | US$70.43 |
| 52 Week Low | US$13.74 |
| Beta | 2.61 |
| 1 Month Change | 38.28% |
| 3 Month Change | -35.93% |
| 1 Year Change | -24.41% |
| 3 Year Change | 139.60% |
| 5 Year Change | 48.91% |
| Change since IPO | 143.27% |
Recent News & Updates
Recent updates
Hims & Hers Q4 Earnings Show Growth Amid GLP-1 Scrutiny
Feb 24The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 46%
Feb 11
Hims & Hers Health - Valuation
🩺 Business Overview Key Metrics Total: -3/17 +1 ✅ Projected Operating Margin: 13.90% +1 ✅ Projected 5-Year Revenue CAGR: 13.87% -2 ❌❌ Last 5-Year ROIC: -7.80% -2 ❌❌ Estimated Cost of Capital: 7.76% (greater than ROIC) -1 ❌ Last 5-Year Shares Outstanding CAGR: +2.65% +2 ✅✅ Projected 5-Year EPS CAGR: 23.29% +0 ⚠️ Projected 5-Year Dividend CAGR: N/A +2 ✅✅ Estimated Debt Rating: Aaa -2 ❌❌ Morningstar Moat: None -2 ❌❌ Morningstar Uncertainty: Very High Hims & Hers Health is a high growth company, being currently on a rapid expansion of its business. This has some advantages like the projected stellar growth of both revenue and EPS but it will also normally represent the dillution of shares to support it and the negative ROIC (lower than the cost of capital) that it should be regularized during the next couple of years.Hims & Hers Health (NYSE:HIMS) Seems To Use Debt Rather Sparingly
Jan 03The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 29%
Nov 18Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 33% Share Price Bounce
Sep 27What You Can Learn From Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S After Its 26% Share Price Crash
Jul 22📈 HIMS' Asymmetric Opportunity, JIN’s Overlooked Strengths, and PROX's Possible Re-Rating
May 21
Hims: The Platform Powering Personalised Healthcare
Platform Play, Not a Pill Company: Hims is building the infrastructure for personalised, direct-to-consumer healthcare across diagnostics, treatment, and prevention, similar to what Amazon did for retHims & Hers Health's (NYSE:HIMS) Performance Is Even Better Than Its Earnings Suggest
May 13After Leaping 89% Hims & Hers Health, Inc. (NYSE:HIMS) Shares Are Not Flying Under The Radar
May 08Hims & Hers Health: GLP-1 Deals De-Risk The Story
Apr 29Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
Apr 23Shareholder Returns
| HIMS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 50.1% | -4.2% | -1.5% |
| 1Y | -24.4% | -18.7% | 21.2% |
Return vs Industry: HIMS underperformed the US Healthcare industry which returned -18.7% over the past year.
Return vs Market: HIMS underperformed the US Market which returned 21.2% over the past year.
Price Volatility
| HIMS volatility | |
|---|---|
| HIMS Average Weekly Movement | 15.9% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: HIMS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HIMS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2,442 | Andrew Dudum | www.hims.com |
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers.
Hims & Hers Health, Inc. Fundamentals Summary
| HIMS fundamental statistics | |
|---|---|
| Market cap | US$5.90b |
| Earnings (TTM) | US$128.37m |
| Revenue (TTM) | US$2.35b |
Is HIMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIMS income statement (TTM) | |
|---|---|
| Revenue | US$2.35b |
| Cost of Revenue | US$614.26m |
| Gross Profit | US$1.73b |
| Other Expenses | US$1.61b |
| Earnings | US$128.37m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.56 |
| Gross Margin | 73.84% |
| Net Profit Margin | 5.47% |
| Debt/Equity Ratio | 179.8% |
How did HIMS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 21:33 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hims & Hers Health, Inc. is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Glen Santangelo | Barclays |
| Allen Lutz | BofA Global Research |